Table 1 Clinical characteristics of the metastatic melanoma patients
Sample ID | Sex | I | LN MTS cell tumor content (%) | Melanoma site | Primary tumor syze | Regional lymph node status | B | M | U | P | BRAF Exon 15 mutation by SS | BRAF Exon 15 mutation by additional method | NRAS Exon 2–3 mutations by SS |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
#1 | M | G | ~ 70 | left lower leg | pT3b | pN3 | 3.55 | 9 | Y | n.a. | WT | PNAClamp™ BRAF Mutation Detection Kit: WT | NM_002524: c.182A > G p.Gln61Arg |
#2 | F | G | > 90 | left upper leg | pT4b | pN3 | 5.53 | 11 | Y | Y | NM_004333: c.1799 T > A p.Val600Glu | PNAClamp™ BRAF Mutation Detection Kit: Mutated | n.d. |
#3 | M | G | > 80 | right lower leg | n.a | pN3 | 2.92 | 3 | n.a | N | NM_004333: c.1799 T > A p.Val600Glu | PNAClamp™ BRAF Mutation Detection Kit: Mutated | n.d. |
#4 | F | G | 80–85 | right arm | pT4a | pN3 | 12.5 | 14 | Y | Y | WT | PNAClamp™ BRAF Mutation Detection Kit: WT | NM_002524: c.181C > A p.Gln61Lys |
#5 | F | G | ~ 80 | left upper leg | pT3a | pN3 | 3.5 | 5–9 | N | Y | NM_004333: c.1799_1800delTGinsAC p.Val600Asp | PNAClamp™ BRAF Mutation Detection Kit: Mutated | WT |
#6 | M | S | ~ 80 | upper back | pT3a | pN2b | 2.75 | 4 | N | N | NM_004333: c.1799 T > A p.Val600Glu | Therascreen™ BRAF Pyro Kit: Mutated | WT |
#7 | M | S | > 80 | left upper leg | pT3b | pN3b | 3.53 | 5 | Y | Y | NM_004333: c.1798_1799delGTinsAA p.Val600Lys | Therascreen™ BRAF Pyro Kit: Mutated | WT |
#8 | F | S | ~ 80 | left forearm | pT3a | pN2b | 2.26 | 3 | N | N | NM_004333: c.1799 T > A p.Val600Glu | Therascreen™ BRAF Pyro Kit: Mutated | WT |
#9 | M | S | > 80 | right lower leg | pT4b | pN3b | 7.45 | 8 | Y | N | WT | Therascreen™ BRAF Pyro Kit: WT | WT |
#10 | F | S | ~ 90 | left foot | pT3b | pN2b | 2.15 | 2 | Y | Y | NM_004333: c.1790 T > G p.Leu597Arg | Therascreen™ BRAF Pyro Kit: Not Detected | WT |
#11 | M | S | ~ 80 | upper back | pT3a | pN2b | 2.84 | 2 | N | N | NM_004333: c.1799 T > A p.Val600Glu | Therascreen™ BRAF Pyro Kit: Mutated | WT |